ReviewMicrobial biotechnology2016
Antibiotic drug discovery.
Review in Microbial biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed.
- Genomic and Phenotypic Characterization ofMicroorganisms · 2026Article
- Antibiotic Mechanisms and Resistance: Molecular Insights and Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2026Review
- Verification and application of an automated real-time antimicrobial susceptibility testing system: for accelerated antibiotic susceptibility testing and high-throughput screening of antibiotic synergistic effects.Journal of biological engineering · 2026Article
- Profiling of Pharmaceutical Sludge Microbiome, Resistome and Secondary Metabolites Using Metagenomics.Indian journal of microbiology · 2025Article
- Last Decade Insights in Exploiting Marine Microorganisms as Sources of New Bioactive Natural Products.Marine drugs · 2025Review
- Use of MALDI-TOF mass spectrometry and IDBac to mine for understudied bacterial genera from the environment.ISME communications · 2025Article
- The WHO's critical bacteria list: scientific response eight years after its implementation and development of an AI-based tool for its monitoring.Frontiers in pharmacology · 2025Article
- Exploring the biosynthesis potential of permafrost microbiomes.Environmental microbiome · 2024Article
- The antibacterial activity of the copper forHeliyon · 2024Article
- Global Analysis of Natural Products Biosynthetic Diversity Encoded in Fungal Genomes.Journal of fungi (Basel, Switzerland) · 2024Article
- Development of Penicillin-Based Carbonic Anhydrase Inhibitors Targeting Multidrug-ResistantJournal of medicinal chemistry · 2024Article
- Potential Anti-Infectious Activity of Essential Oil Chemotypes ofPlants (Basel, Switzerland) · 2024Article
- Combatting Antibiotic Resistance: Regulatory Exclusivities for New Antibiotic Development in the United States and Europe.Infectious diseases & immunity · 2024Review
- Mining Biosynthetic Gene Clusters ofMicroorganisms · 2024Article
- Synergistic antibacterial effects of exopolysaccharides/nickel-nanoparticles composites against multidrug-resistant bacteria.Scientific reports · 2023Article
- Chemical genetic approaches for the discovery of bacterial cell wall inhibitors.RSC medicinal chemistry · 2023Review
- A potential strategy against clinical carbapenem-resistant Enterobacteriaceae: antimicrobial activity study of sweetener-decorated gold nanoparticles in vitro and in vivo.Journal of nanobiotechnology · 2023Article
- Isolation and Screening of Antibacterial Activity ofArchives of Razi Institute · 2023Article
- Isopropoxy Benzene Guanidine AmelioratesInternational journal of molecular sciences · 2023Article
- MS/MS-Based Molecular Networking: An Efficient Approach for Natural Products Dereplication.Molecules (Basel, Switzerland) · 2022Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the threat posed by the increase of highly resistant pathogenic bacteria, there is an urgent need for new antibiotics; all the more so since in the last 20 years, the approval for new antibacterial agents had decreased. The field of natural product discovery has undergone a tremendous development over the past few years. This has been the consequence of several new and revolutionizing drug discovery and development techniques, which is initiating a 'New Age of Antibiotic Discovery'. In this review, we concentrate on the most significant discovery approaches during the last and present years and comment on the challenges facing the community in the coming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.